Dashboard
Manage Tickers

MGNX


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

reported-sunday-macrogenics-to-present-phase-2-results-from-tamarack-trial-on-innovative-cancer-treatment-at-esmo-2024
Reported Sunday, MacroGenics To Present Ph...
09/09/2024 07:15:19

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializ...

hc-wainwright--co-reiterates-neutral-on-macrogenics-maintains-4-price-target
HC Wainwright & Co. Reiterates Neutral on ...
08/21/2024 12:15:16

HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.

evaluating-macrogenics-insights-from-8-financial-analysts
Evaluating Macrogenics: Insights From 8 Fi...
08/15/2024 15:01:08

citigroup-maintains-buy-on-macrogenics-lowers-price-target-to-14
Citigroup Maintains Buy on Macrogenics, Lo...
08/15/2024 14:25:04

Citigroup analyst Yigal Nochomovitz maintains Macrogenics (NASDAQ:MGNX) with a Buy and lowers the price target from $16 to $14.

bmo-capital-maintains-market-perform-on-macrogenics-lowers-price-target-to-5
BMO Capital Maintains Market Perform on Ma...
08/07/2024 15:12:31

BMO Capital analyst Etzer Darout maintains Macrogenics (NASDAQ:MGNX) with a Market Perform and lowers the price target from ...

macrogenics-q2-eps-089-misses-059-estimate-sales-1080m-miss-2124m-estimate
Macrogenics Q2 EPS $(0.89) Misses $(0.59) ...
08/06/2024 20:38:09

Macrogenics (NASDAQ:MGNX) reported quarterly losses of $(0.89) per share which missed the analyst consensus estimate of $(0.59)...

btig-downgrades-macrogenics-to-neutral
BTIG Downgrades Macrogenics to Neutral
08/01/2024 18:08:19

BTIG analyst Kaveri Pohlman downgrades Macrogenics (NASDAQ:MGNX) from Buy to Neutral.

hc-wainwright--co-reiterates-neutral-on-macrogenics-maintains-4-price-target
HC Wainwright & Co. Reiterates Neutral on ...
08/01/2024 10:17:55

HC Wainwright & Co. analyst Robert Burns reiterates Macrogenics (NASDAQ:MGNX) with a Neutral and maintains $4 price target.

jmp-securities-maintains-market-outperform-on-macrogenics-lowers-price-target-to-8
JMP Securities Maintains Market Outperform...
07/31/2024 18:16:44

JMP Securities analyst Silvan Tuerkcan maintains Macrogenics (NASDAQ:MGNX) with a Market Outperform and lowers the price tar...

after-reporting-five-patient-deaths-data-committee-recommends-macrogenics-halt-prostate-cancer-trial
After Reporting Five Patient Deaths, Data ...
07/31/2024 17:45:20

MacroGenics will discontinue vobra duo for remaining mCRPC participants after five deaths. New data to be presented at ESMO 202...

barclays-maintains-overweight-on-macrogenics-lowers-price-target-to-8
Barclays Maintains Overweight on Macrogeni...
07/31/2024 14:30:10

Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $9 to $8.

Core News & Articles
Market-Moving News for July 31st
07/31/2024 12:28:10

MHUA: 121% | Meihua International Announced That Its NT-2000 Surgical Path Analysis System Successfully Supported The World'...

pinterest-issues-weak-revenue-forecast-joins-groupon-o-i-glass-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Pinterest Issues Weak Revenue Forecast, Jo...
07/31/2024 12:27:51

guggenheim-downgrades-macrogenics-to-neutral
Guggenheim Downgrades Macrogenics to Neutral
07/31/2024 10:09:11

Guggenheim analyst Kelsey Goodwin downgrades Macrogenics (NASDAQ:MGNX) from Buy to Neutral.

b-riley-securities-downgrades-macrogenics-to-neutral-lowers-price-target-to-5
B. Riley Securities Downgrades Macrogenics...
07/31/2024 09:58:44

B. Riley Securities analyst Mayank Mamtani downgrades Macrogenics (NASDAQ:MGNX) from Buy to Neutral and lowers the price tar...

why-amd-shares-are-trading-higher-by-over-9-here-are-20-stocks-moving-premarket
Why AMD Shares Are Trading Higher By Over ...
07/31/2024 09:46:00

macrogenics-provides-vobramitamab-duocarmazine-update-abstract-of-clinical-data-accepted-for-poster-presentation-at-esmo-congress-2024-in-september-gives-tamarack-study-update-says-patient-safety-is-our-top-priority-and-having-reached-the-studys-primary-endpoint-we-decided-to-discontinue-additional-dosing-for-the-remaining-tamarack-participants-who-had-not-yet-completed-treatment
MacroGenics Provides Vobramitamab Duocarma...
07/30/2024 20:20:54

TAMARACK Study UpdateMacroGenics completed enrollment of the TAMARACK study in the fourth quarter of 2023, and plans to present...

Core News & Articles
MacroGenics Achieves $100M In Milestones R...
07/30/2024 20:19:14

MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializ...

expert-outlook-macrogenics-through-the-eyes-of-7-analysts
Expert Outlook: Macrogenics Through The Ey...
07/29/2024 16:00:51

barclays-maintains-overweight-on-macrogenics-lowers-price-target-to-9
Barclays Maintains Overweight on Macrogeni...
07/29/2024 15:30:29

Barclays analyst Peter Lawson maintains Macrogenics (NASDAQ:MGNX) with a Overweight and lowers the price target from $14 to $9.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION